ARTICLE | Discovery & Translation

Science spotlight: Biotechs discover new checkpoint target, and more

BioCentury’s roundup of translational innovations

May 4, 2024 1:50 AM UTC

Shanghai Xunbaihui Biotechnology Co. Ltd. and GV20 Therapeutics LLC identified an immunoglobulin protein as an immune checkpoint expressed on tumor cells that suppresses NK cell cytotoxicity.

Over 65% of all tumors are antigen-presentation-deficient because of loss of HLA-I. Normally, HLA-I acts as a marker of “self,” and cells that lack HLA-I, for example due to viral infection, are killed by NK cells. Somehow, tumor cells avoid this fate...